drugset / Trial / NCT06831864

Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka

NCT06831864

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this trial is to see if the research team can successfully recruit participants and carry out study related procedures in Sri Lanka. This will help the research team plan and execute a future large-scale trial in Sri Lanka. The secondary objective is to assess whether a polypill for patients with heart failure with reduced ejection fraction (a type of heart condition) may help patients adhere to medications without an increase in serious adverse events. An exploratory objective is to understand the process of implementation. Participants will be randomly assigned to one of two groups, intervention or usual care. The intervention group will be given four guideline-recommended medications for heart failure with reduced ejection fraction, combined in one over-encapsulated pill, with three dose strength options (at the discretion of their treating physician). Both groups will be observed over 4-weeks of follow-up to assess their medication adherence, clinical symptoms, laboratory measures, health related quality of life, and need for medication adjustment amongst other measures.

Timeline

Start
2025-02-15
Primary completion
2025-05-05
Completion
2025-05-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bisoprolol Other / unclassified 2.5 mg
Subject Bisoprolol Other / unclassified 5 mg
Subject Bisoprolol Other / unclassified 10 mg
Subject Dapagliflozin Small molecule 10 mg
Subject Eplerenone Unknown 25 mg
Subject Eplerenone Unknown 50 mg
Subject Losartan Other / unclassified 25 mg
Subject Losartan Other / unclassified 50 mg
Subject Losartan Other / unclassified 100 mg